| scholarly article | Q13442814 |
| P50 | author | Ulrich M. Zanger | Q56961651 |
| P2093 | author name string | Kathrin Klein | |
| P2860 | cites work | Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens | Q74266054 |
| Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus | Q80094886 | ||
| Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients | Q80337036 | ||
| A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6 | Q80755986 | ||
| CYP3A5 genetic polymorphisms in different ethnic populations | Q81656400 | ||
| Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers | Q82338313 | ||
| CYP2B6 and OPRM1 gene variations predict methadone-related deaths | Q82886892 | ||
| Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms | Q83150083 | ||
| Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether | Q84540301 | ||
| Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262 | Q84707349 | ||
| Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4 | Q93923339 | ||
| Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation | Q95825735 | ||
| The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals | Q23912648 | ||
| Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET). | Q23919095 | ||
| Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution | Q24294558 | ||
| Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A | Q24317436 | ||
| Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study | Q24633579 | ||
| Structures of Cytochrome P450 2B6 Bound to 4-Benzylpyridine and 4-(4-Nitrobenzyl)pyridine: Insight into Inhibitor Binding and Rearrangement of Active Site Side Chains | Q27672416 | ||
| VMD: visual molecular dynamics | Q27860554 | ||
| The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene | Q28137778 | ||
| Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6 | Q28256125 | ||
| Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants | Q28260351 | ||
| CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes | Q28277878 | ||
| Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients | Q28294491 | ||
| Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation | Q28299225 | ||
| Involvement of human liver cytochrome P4502B6 in the metabolism of propofol | Q28362299 | ||
| A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation | Q32182262 | ||
| Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. | Q33269667 | ||
| Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation | Q33431427 | ||
| Efavirenz in the therapy of HIV infection. | Q33607011 | ||
| The role of CYP2B6 in human xenobiotic metabolism | Q33719834 | ||
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. | Q33747406 | ||
| Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers | Q33881813 | ||
| CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. | Q33918576 | ||
| Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine | Q34000752 | ||
| Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver | Q34018308 | ||
| Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation | Q34310059 | ||
| Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes | Q34313342 | ||
| Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. | Q34426985 | ||
| The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation | Q34457423 | ||
| Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes | Q34620579 | ||
| Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms | Q44879623 | ||
| Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles | Q44931383 | ||
| Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis | Q44973876 | ||
| Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools | Q45088644 | ||
| Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods | Q45132328 | ||
| Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. | Q45204313 | ||
| Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay | Q45207281 | ||
| Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based | Q45225371 | ||
| A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site. | Q45275839 | ||
| Artemisinin--a possible CYP2B6 probe substrate? | Q45813718 | ||
| Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population | Q46116827 | ||
| Successful genotype-tailored treatment with small-dose efavirenz | Q46135800 | ||
| Clinical impact of patient population differences and genomic variation in efavirenz therapy | Q46406628 | ||
| Cyclophosphamide and CYP2B6 | Q46479542 | ||
| High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe | Q46526697 | ||
| Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation | Q46551914 | ||
| CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. | Q46681251 | ||
| Pharmacogenetics of cyclophosphamide in patients with hematological malignancies | Q46720073 | ||
| Role of CYP2B6 in stereoselective human methadone metabolism | Q46739706 | ||
| Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz | Q46793035 | ||
| Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz | Q46845944 | ||
| Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study | Q46878731 | ||
| Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects | Q46891654 | ||
| Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. | Q46965067 | ||
| Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. | Q47710627 | ||
| Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine | Q48251035 | ||
| Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. | Q50064959 | ||
| Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. | Q50088360 | ||
| Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. | Q50922300 | ||
| Further characterization of the expression in liver and catalytic activity of CYP2B6. | Q51502170 | ||
| Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues | Q52105585 | ||
| Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. | Q53547764 | ||
| High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study | Q56829831 | ||
| Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers | Q57550254 | ||
| Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment | Q57550282 | ||
| Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide | Q58483640 | ||
| Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation | Q58483705 | ||
| Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes | Q58483756 | ||
| Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes | Q59153191 | ||
| Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population | Q60182643 | ||
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver | Q60787038 | ||
| The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status | Q62232173 | ||
| CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans | Q62494307 | ||
| Induction of the unspecific microsomal hydroxylase in the human liver | Q70042657 | ||
| Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 | Q73201582 | ||
| Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs | Q73755207 | ||
| CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction | Q37075089 | ||
| Inhibition and induction of human cytochrome P450 enzymes: current status | Q37212794 | ||
| Plasticity of CYP2B enzymes: structural and solution biophysical methods | Q37429225 | ||
| Cytochrome P450-mediated metabolism in the human gut wall | Q37465350 | ||
| A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans | Q37471061 | ||
| Cytochrome P450 2B6: function, genetics, and clinical relevance | Q38059848 | ||
| Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine | Q38307565 | ||
| Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda | Q38878356 | ||
| Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo | Q40021883 | ||
| Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver | Q40028874 | ||
| Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. | Q40447949 | ||
| Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers | Q40587140 | ||
| Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. | Q40853675 | ||
| Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin | Q40914424 | ||
| Human CYP2B6: expression, inducibility and catalytic activities | Q40931711 | ||
| New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis | Q41584700 | ||
| Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. | Q41934777 | ||
| Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs | Q42217729 | ||
| The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches | Q42717866 | ||
| Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). | Q43047773 | ||
| ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir | Q43169873 | ||
| Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes | Q43514687 | ||
| Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender | Q43673470 | ||
| Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor | Q43705734 | ||
| Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism | Q43957702 | ||
| Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients | Q44281312 | ||
| A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression | Q44305000 | ||
| Functional characterization of cytochrome P450 2B6 allelic variants | Q44365469 | ||
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity | Q44391267 | ||
| Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain | Q44482991 | ||
| Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. | Q44502138 | ||
| Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes | Q44550582 | ||
| Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression | Q44613137 | ||
| Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine | Q44620932 | ||
| Human hepatic CYP2B6 developmental expression: the impact of age and genotype | Q44877337 | ||
| Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer | Q34682560 | ||
| Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study | Q34763589 | ||
| Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide | Q34780478 | ||
| CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme | Q34824471 | ||
| Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase c | Q35188159 | ||
| Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme | Q35415762 | ||
| Cytochrome P450 enzymes in the brain: emerging evidence of biological significance | Q35570962 | ||
| Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon | Q35647132 | ||
| Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo | Q35647150 | ||
| Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy | Q35654120 | ||
| Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism | Q35827416 | ||
| Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo | Q35846912 | ||
| Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism | Q35929431 | ||
| CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment | Q36024652 | ||
| Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent | Q36070182 | ||
| Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment | Q36079108 | ||
| Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme | Q36174280 | ||
| Stereoselective and regiospecific hydroxylation of ketamine and norketamine | Q36186055 | ||
| Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis | Q36336024 | ||
| Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers | Q36406247 | ||
| Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts | Q36406310 | ||
| Bioactivation of chlorpyrifos by CYP2B6 variants | Q36462008 | ||
| Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. | Q36468142 | ||
| Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index | Q36562516 | ||
| Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir | Q36593838 | ||
| Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation | Q36631976 | ||
| The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. | Q36638423 | ||
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach | Q36720920 | ||
| Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants | Q36734592 | ||
| Expression and function of cytochrome p450 in brain drug metabolism | Q36822882 | ||
| Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance | Q36885659 | ||
| Pharmacogenetics of anti-HIV drugs | Q36947067 | ||
| Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity | Q36952243 | ||
| Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. | Q36998968 | ||
| P304 | page(s) | 24 | |
| P577 | publication date | 2013-03-05 | |
| P1433 | published in | Frontiers in Genetics | Q2499875 |
| P1476 | title | Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance | |
| P478 | volume | 4 |
| Q90703148 | A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics |
| Q92533935 | Adverse Drug Reactions Associated with CYP 2B6 Polymorphisms in HIV/AIDS-Treated Patients in Yaoundé, Cameroon |
| Q99237781 | Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities |
| Q38097097 | Anti-Parkinson's disease drugs and pharmacogenetic considerations |
| Q40206331 | CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil |
| Q37615768 | CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. |
| Q54260617 | CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. |
| Q90248911 | CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers |
| Q28552450 | CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide |
| Q41048998 | Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics |
| Q90731111 | Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications |
| Q34946016 | Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo |
| Q98284627 | Circulating miRNAs as biomarkers for CYP2B6 enzyme activity |
| Q64110710 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy |
| Q36893698 | Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations |
| Q52338012 | Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog. |
| Q50682107 | Current Concepts in Methadone Metabolism and Transport. |
| Q36634466 | Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma |
| Q37062614 | Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation |
| Q35745266 | Differences in Methadone Metabolism by CYP2B6 Variants |
| Q53234957 | Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations. |
| Q49848244 | Effects of Cytochrome P450 Single Nucleotide Polymorphisms on Methadone Metabolism and Pharmacodynamics. |
| Q55262171 | Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects. |
| Q89597948 | Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study |
| Q55506508 | Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype. |
| Q53776103 | Functional allele and genotype frequencies of CYP1A2, CYP2B6 and iNOS among mainland Chinese Tibetan, Mongolian, Uygur and Han populations. |
| Q92229330 | Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle |
| Q41058699 | Functional importance of a peripheral pocket in mammalian cytochrome P450 2B enzymes. |
| Q40492924 | Functional polymorphisms of xenobiotics metabolizing enzymes-a research topic |
| Q33736174 | Genetic Testing for Opioid Pain Management: A Primer |
| Q33833207 | Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research |
| Q57155498 | Genetics of perioperative pain management |
| Q37400962 | High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6. |
| Q37590883 | Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays |
| Q38175870 | Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz |
| Q95270356 | In Vitro Assessment of the Interaction Potential of Ocimum basilicum (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism |
| Q35816039 | In Vitro Generation of Functional Liver Organoid-Like Structures Using Adult Human Cells |
| Q47899552 | Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients |
| Q40786076 | Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings. |
| Q37358704 | Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers |
| Q64950487 | Inter-Individual Variability in Xenobiotic-Metabolizing Enzymes: Implications for Human Aging and Longevity. |
| Q90970881 | Inverse PCR to perform long-distance haplotyping: main applications to improve preimplantation genetic diagnosis in hemophilia |
| Q33798516 | Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. |
| Q58612379 | Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype |
| Q55476359 | Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects. |
| Q52815923 | Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes. |
| Q36342286 | Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism |
| Q100527261 | Model-based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer |
| Q37344778 | Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs |
| Q47906608 | Pharmacogenetic considerations for HIV treatment in different ethnicities: an update |
| Q38782609 | Pharmacogenetic considerations in the treatment of HIV. |
| Q38751555 | Pharmacogenetics of Ketamine-Induced Emergence Phenomena: A Pilot Study. |
| Q47425192 | Pharmacogenetics of Methadone Response |
| Q38222510 | Pharmacogenomics of methadone maintenance treatment |
| Q92528050 | Pharmacogenomics of poor drug metabolism in Greyhounds: Cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization |
| Q99252113 | Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping |
| Q42713259 | Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy |
| Q52330065 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review. |
| Q58096508 | Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity |
| Q36666343 | Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesia |
| Q37538760 | Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition |
| Q54659609 | Pregnancy and pharmacogenomics in the context of drug metabolism and response. |
| Q38188600 | Priority pharmacogenetics for the African continent: focus on CYP450. |
| Q50521741 | Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims. |
| Q39430407 | Review of Opioid Pharmacogenetics and Considerations for Pain Management |
| Q37153012 | Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers |
| Q92562828 | Ser100-Phosphorylated RORα Orchestrates CAR and HNF4α to Form Active Chromatin Complex in Response to Phenobarbital to Regulate Induction of CYP2B6 |
| Q49215469 | Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6. |
| Q35106387 | The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities |
| Q51628497 | The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity. |
| Q58805294 | The Prevalence of Gene Polymorphisms in Malaria-endemic Population of Timor in East Nusa Tenggara Indonesia |
| Q89065810 | The Role of Genetic Polymorphisms in Chronic Pain Patients |
| Q96126184 | The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial |
| Q57295021 | The use of PBPK modeling across the pediatric age range using propofol as a case |
| Q92016205 | Toward precision prescribing for methadone: Determinants of methadone deposition |
| Q46246116 | Use of phenoxyaniline analogs to generate biochemical insights into polybrominated diphenyl ether interaction with CYP2B enzymes |
| Q57807871 | Zebrafish (Danio rerio) Water Tank Model for the Investigation of Drug Metabolism: Progress, Outlook, and Challenges |
Search more.